U.S. Markets open in 5 hrs 49 mins

Opexa Therapeutics, Inc. (OPXA)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.89-0.01 (-1.22%)
At close: 3:59PM EDT
People also watch
CYTXCURPSTIOSIRCYCC
  • $OPXAW AND $OPXA PRESS RELEASE OUT SOON BUY AND HOLD U WILL THANK ME $$$ TARGET PRICE OF $5.00
  • $OPXAW AND $OPXA is gonna shoot up big bucks here biotech NEWS!! RATED A STRING BUY BUY BUY AND HOLD!!! TARGET PRICE $6.00
  • I have a feeling OPXA will see a pullback now. What yall think? Yo you should really check out awe.SOME-Stock-S, they seem on point with their stocks.
  • Ready for take off
  • Wow. Good volume. Nice push up! Let's go OPXA!!!
  • Imageizayadragon
  • Monster Microcaps Alert to OPXA shareholders. Clean Energy Technologies (CETY) opened their Europe Sales and Service Center for Europe sales and to serve 65 existing customers with CETY’s General Electric clean energy heat recovery systems and has already sold the first of hundreds of units to come.

    Each CETY Heat Recovery System sells for $300,000 and market demand is reported to several BILLION DOLLARS.

    CETY purchased Heat Recovery Systems in 2015 from General Electric and products are now very attractive to huge unmet markets and can achieve over $250 million annual sales within the next 2 years. Demand for conversion of wasted heat to electrical energy in big applications is VERY LARGE AND UNMET.

    Shares are steal with target of $.20 by year end and higher in 12 months.

    https://finance.yahoo.com/news/clean-energy-technologies-inc-secures-144700111.html

    Clean Energy Technologies, Inc. Secures New Order for Waste Biomass Application in Europe
    COSTA MESA, Calif., July 12, 2017 /PRNewswire/ -- Clean Energy Technologies, Inc. (CETY) announced today that its subsidiary Heat Recovery Solutions has secured a new Clean CycleTM generator order for a Waste Biomass application in Europe. Growing d
    finance.yahoo.com
  • Maybe will see $1.50+ by end of the week!!..
  • $OPXA IS A GUARANTEED WINNER trade.they are a bio tech which is the only bio who is working on a cure for neurological conditions such as multiple sclerosis. RATED A Strong BUY AND HOLD > ONLY .80 CENTS Target price is $12.00 BUY BUY BUY AND HOLD U WILL THANK ME!!!
  • Let's see 2 dollars 💵
  • Bull flag??
  • Gonna Shoot really high up TARGET PRICE of $12.00 merger with Huge bio company BUY AND HOLD=$$$$
  • IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL

    Intelgenx (IGXT)

    MarketCap $50 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.80

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017

    http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

  • AVGR running up
  • So opxa will be absorbed into acer and shares converted upon merger approval. I can't wait for this next shareholders meeting
  • So what happens to the opxaw stocks with this merger?
  • BCDA is the next one!
  • Missed it by .01. Had a buy in at 1.04 and it touched 1.05 then up from there
  • spi
  • I see OPXAW traded at 20 cents today when the stock (OPXA) is trading at 62 cents. Keep in mind, last I checked it took 8 warrants and $20 cash to purchase 1 share of stock and the warrants expire in March 2018.